Heron Therapeutics, Inc. (HRTX) Earnings History
Net Loss37 years of earnings data (1989–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Heron Therapeutics, Inc. (HRTX) Earnings Overview
As of June 23, 2026, Heron Therapeutics, Inc. (HRTX) reported trailing twelve-month net income of -$31M, reflecting -34.7% year-over-year growth. The company earned $-0.16 per diluted share over the past four quarters, with a net profit margin of -13.0%.
Looking at the long-term picture, HRTX's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2000.
Heron Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$129M net income, -341.5% margin), PCRX ($9M net income, 1.0% margin), ACRS (-$70M net income, -829.6% margin), HRTX has outperformed on profitability metrics. Compare HRTX vs PACB →
HRTX Earnings vs Peers
Earnings metrics vs comparable public companies
HRTX Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$20M | -48.7% | -$3M | $-0.12 | -13.0% | -1.6% |
| 2024 | -$14M | +87.7% | -$12M | $-0.09 | -9.4% | -8.0% |
| 2023 | -$111M | +39.3% | -$111M | $-0.80 | -87.0% | -87.1% |
| 2022 | -$182M | +17.5% | -$175M | $-1.67 | -169.1% | -162.2% |
| 2021 | -$221M | +2.9% | -$218M | $-2.24 | -255.6% | -252.3% |
| 2020 | -$227M | -11.0% | -$228M | $-2.50 | -256.4% | -257.4% |
| 2019 | -$205M | -14.5% | -$211M | $-2.50 | -140.3% | -144.3% |
| 2018 | -$179M | +9.4% | -$184M | $-2.44 | -230.8% | -237.4% |
| 2017 | -$197M | -14.1% | -$195M | $-3.65 | -641.9% | -632.4% |
| 2016 | -$173M | -77.4% | -$171M | $-4.57 | -13537.4% | -13363.2% |
| 2015 | -$98M | -27.8% | -$97M | $-2.95 | - | - |
| 2014 | -$76M | -38.1% | -$75M | $-2.87 | - | - |
| 2013 | -$55M | -136.8% | -$54M | $-3.42 | - | - |
| 2012 | -$23M | -97.6% | -$24M | $-1.91 | -3614.2% | -3689.0% |
| 2011 | -$12M | -60.8% | -$11M | $-1.18 | -1828.8% | -1712.4% |
| 2010 | -$7M | +26.7% | -$10M | $-3.70 | -564.6% | -763.6% |
| 2009 | -$10M | +56.6% | -$10M | $-6.15 | -795.2% | -812.2% |
| 2008 | -$23M | -14.7% | -$23M | $-15.00 | -6266.9% | -6353.7% |
| 2007 | -$20M | -482.9% | -$24M | $-20.80 | -4893.9% | -5736.2% |
| 2006 | $5M | +164.1% | -$19M | $66.25 | 97.7% | -349.9% |
| 2005 | -$8M | +11.0% | -$8M | $-26.15 | -152.3% | -157.2% |
| 2004 | -$9M | -111.3% | -$9M | $-32.20 | -170.6% | -172.4% |
| 2003 | -$4M | -15.5% | -$7M | $-16.98 | -90.0% | -136.4% |
| 2002 | -$4M | -50.3% | -$5M | $-14.81 | -65.0% | -86.9% |
| 2001 | -$3M | -129.4% | -$7M | $-9.92 | -57.3% | -167.1% |
| 2000 | $9M | +507.2% | -$4M | $33.60 | 254.1% | -128.0% |
| 1999 | -$2M | +22.2% | -$2M | $9.60 | -10.3% | -8.3% |
| 1998 | -$3M | -50.0% | $3M | $9.60 | -13.5% | 12.5% |
| 1997 | -$2M | +80.9% | -$1M | $-32.00 | -10.5% | -6.4% |
| 1996 | -$9M | +0.0% | -$9M | $-40.96 | -50.3% | -45.5% |
| 1995 | -$9M | +4.1% | -$9M | $-45.60 | -58.4% | -53.4% |
| 1994 | -$10M | +1.0% | -$9M | $-48.87 | -61.6% | -56.6% |
| 1993 | -$10M | -76.8% | -$10M | $-58.03 | -49.7% | -52.3% |
| 1992 | -$6M | -30.2% | -$6M | $-34.50 | -76.7% | -87.7% |
| 1991 | -$4M | -10.3% | -$4M | $-34.40 | -153.6% | -142.9% |
| 1990 | -$4M | +13.3% | -$5M | $-32.14 | -162.5% | -195.8% |
| 1989 | -$5M | - | -$5M | $-37.86 | -160.7% | -189.3% |
Download Data
Export HRTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HRTX — Frequently Asked Questions
Quick answers to the most common questions about buying HRTX stock.
What is HRTX earnings per share (EPS)?
HRTX trailing twelve-month (TTM) diluted EPS is $-0.16, reflecting -34.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Heron Therapeutics, Inc.'s net income?
Heron Therapeutics, Inc. (HRTX) trailing twelve-month net income is $-31M as of 2025. Earnings declined -34.7% year-over-year.
Is HRTX profitable?
HRTX is not currently profitable on a TTM basis, reporting a net loss of $-31M. Net margin is -13.0%. Investors should monitor for a return to profitability.
What is HRTX's earnings growth rate?
HRTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are HRTX's profit margins?
Heron Therapeutics, Inc. net profit margin is -13.0%, operating margin is -1.6%, and gross margin is +73.3%. Below-average margins reflect competitive or cost pressures. Return on Equity is -140.9%.
Is HRTX growing earnings?
HRTX earnings are declining — EPS fell -34.7% year-over-year. TTM net income dropped to $-31M. This contrasts with the 5-year CAGR of N/A.
What was HRTX's best earnings year?
Heron Therapeutics, Inc.'s highest annual net income on record is $9M, achieved in fiscal year 2000. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were HRTX's earnings last quarter?
HRTX's most recent reported quarter was Q1 2026. Net income was $-8M with diluted EPS of $-0.04. For a full breakdown of all quarters, see the quarterly earnings table on this page.